Immunotherapy has become a part of the standard-of-care treatment for patients with certain cancers. In this issue of the American Journal of Hematology/Oncology, a peer-reviewed resource for oncology education and the official journal of Physicians’ Education Resource^®, LLC, we feature 2 articles on immunotherapy: In the first, Elizabeth A. Mittendorf, MD, PhD, and Kelly K. Hunt, MD, focus on emerging results from clinical trials evaluating immunotherapy in breast cancer. In the second, Sarah B. Goldberg, MD, summarizes progress to date regarding the development of immunotherapies targeting the PD-1 axis for non-small cell lung cancer (NSCLC).

In the past decade, advances in the treatment of NSCLC have included the approval of antiangiogenesis inhibitors such as bevacizumab and ramucirumab, and tyrosine kinase inhibitors (TKIs) such as erlotinib. Some success has been observed in trials of antiangiogenesis inhibitors combined with EGFR TKIs in the general population. In this issue, Edward S. Kim, MD, details the combination trials that are currently ongoing in the EGFR mutation-positive population.

Bobby C. Liaw, MD, and William K. Oh, MD, explore the current controversy on the use of docetaxel for metastatic hormone-sensitive prostate cancer, including a review of the results of the recently published CHAARTED and STAMPEDE trials.

Carlie K. Thompson, MD, Martin Eklund, PhD, and Laura J. Esserman, MD, MBA, review the “great mammography debate,” and propose that controversies in breast cancer screening be settled once and for all with a modern-era screening trial.

Our CME article this month reviews factors that impact adherence to oral cancer therapies and some strategies for improving adherence, with the goal of improving outcomes in the real-world setting.

Michael J. Hennessy, Sr
Chairman and Chief Executive Officer